Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02221310 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS (NCT02221310)

Trial Description
Targeted immune therapy with gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) in combination with chemotherapy followed by allogeneic stem cell transplantation will be given to patients with high risk acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).

This trial is sponsored by New York Medical College. [1]

Study Data

  • Conditions:
    • Acute Myelogenous Leukemia (AML)
    • Myelodysplastic Syndrome (MDS)
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 25
  • Start: November 2011
  • Estimated Completion: December 2018

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 21, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar